Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Eczema diagnosis by 1 to 3 years · infants
Skin care intervention showed no clear difference in eczema diagnosis by 1 to 3 years compared with standard skin care or no skin care intervention (moderate certainty).
1 finding from 1 review
IgE‐mediated food allergy (oral food challenge) by 1 to 3 years · infants
Skin care intervention showed no clear difference in igE‐mediated food allergy (oral food challenge) by 1 to 3 years compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Slippages (over the intervention period) · infants
Skin care intervention showed no clear difference in slippages (over the intervention period) compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Skin infection (over the intervention period) · infants
Skin care intervention probably leads to higher skin infection (over the intervention period) compared with standard skin care or no skin care intervention (moderate certainty).
1 finding from 1 review
Stinging/allergic reactions to moisturisers (over the intervention period) · infants
Skin care intervention showed no clear difference in stinging/allergic reactions to moisturisers (over the intervention… compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Time to onset of eczema · infants
Skin care intervention showed no clear difference in time to onset of eczema compared with standard skin care or no skin care intervention (moderate certainty).
1 finding from 1 review
Parent report of immediate reaction to common food allergen (at 2 years) · infants
Skin care intervention showed no clear difference in parent report of immediate reaction to common food allergen (at 2… compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Allergic sensitisation to a food allergen (at 1 to 3 years) · infants
Skin care intervention showed no clear difference in allergic sensitisation to a food allergen (at 1 to 3 years) compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review